Modified GRF(1-29)
Modified GRF(1-29) — commonly mislabeled as "CJC-1295 without DAC" — is a synthetic analog of the first 29 amino acids of native GHRH with four amino acid substitutions (Ala2→D-Ala, Asn8→Gln, Ala15→Ala(Me), Met27→Leu) that protect against enzymatic degradation (DPP-IV, trypsin). This extends its half-life from ~7 minutes (native GHRH) to ~30 minutes — long enough to produce a meaningful GH pulse but short enough to preserve natural pulsatile GH physiology. This is the key advantage over CJC-1295 DAC: mod-GRF 1-29 triggers discrete GH pulses that mimic natural secretion patterns, then clears, allowing GH receptor resensitization between doses. Combined with a GHRP (ipamorelin being the preferred partner), this produces the "cleanest" GH-amplifying protocol available — physiologically pulsatile, no cortisol/prolactin elevation (when paired with ipamorelin), and no sustained insulin resistance. The standard of care in modern peptide therapy for anti-aging, recovery, and body composition.
Evidence
No score yet
Safety
Unknown safety profile
Clinical Status
Preclinical (modified research analog of sermorelin)
Last Sync
Not synced yet
Last Reviewed
Not reviewed yet
Dosing
Set height & weight in Settings to see your dose.
Pharmacology
Evidence Score
Plain-English Snapshot
Modified GRF(1-29) is currently categorized as a peptide compound.
Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.
Safety scoring is incomplete. Start conservatively and monitor carefully.
Core mechanism
GHRH receptor agonist; produces discrete, physiological GH pulses (unlike DAC variant which creates sustained elevation). Four amino acid substitutions resist DPP-IV degradation.
Practical Context
Strongest current signals
No indexed study summaries yet.